Cegedim Relationship Management has announced the release of a key thought leadership white paper, Emerging Markets Today and Tomorrow: Insights on Healthcare, Pharmaceuticals and Future Trends in the BRIC Landscape, which highlights first-hand market insights from Cegedim experts in Brazil, Russia, India and China (BRIC). The report outlines the critical relationship between evolving BRIC healthcare climates and pharmaceutical markets; and the best strategies to boost growth in each of the emerging markets.

Driving New and Continued Growth in BRIC Countries Pivots on Navigating Unique Healthcare Environments and Local Market Obstacles

The stakes are rising for improving commercial performance in emerging markets. Five years ago, emerging markets were responsible for just 5% of pharmaceutical companies’ profits; today, they make up 20 - 30% of profits. Shifts in the BRIC landscape will prompt companies to optimize their commercial strategies with a better understanding of local markets and stakeholder networks.

“Our proven legacy within BRIC markets empowers us to deliver the most relevant insights on industry trends and challenges facing each pharmaceutical target country,” said Laurent Labrune, Chief Executive Officer of Cegedim Relationship Management. “Our on-site presence in each BRIC country enables us to furnish companies with the game-changing industry knowledge required to innovate beyond the challenges of rapidly evolving healthcare environments.”

Following are brief highlights from the report on each of the BRIC pharmaceutical markets:

• Success in Brazil requires the cultivation of deeper relationships with large drug distributors and physicians while also capturing the growing out-of-pocket and reimbursement-based segments.
• In Russia, companies must embrace new initiatives to nationalize drug production and greater limitations on sales visits with doctors, drug pricing and promotion; and drive a comprehensive OTC campaign remembering that most new drugs will come from local manufacturers.
• In India, superior market access strategies depend on targeting key states rather than struggling to cover the entire nation. Companies must leverage local organizations for intellectual talent and affordable workforces, as well as existing distribution and manufacturing infrastructures.
• With China projected to become a global top tier pharma market, it is imperative for companies to heed a constantly shifting industry by outlining a clear vision, maintaining flexible business strategies and offering a diverse product portfolio and physician education initiatives.

Please click here to access the report, Emerging Markets Today and Tomorrow: Insights on Healthcare, Pharmaceuticals and Future Trends in the BRIC Landscape.